How would you further evaluate and treat this patient? Heart failure with preserved ejection fraction is a heterogeneous syndrome. The diagnosis of the condition requires ruling out potential ...

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

Background Early heart failure (HF) diagnosis is crucial to ensure that optimal guideline-directed medical therapy (GDMT) is ...

DelveInsight's Heart failure with Reduced Ejection Fraction Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

Research led by Professor Hai-Ling Margaret Cheng (BME) opens the door to earlier treatment and better outcomes ...

Experts warn that this early stage of heart failure, classified as Stage B, often goes unnoticed but can lead to severe ...

The key to treating congestive heart failure is addressing the underlying causes, and treatment is highly tailored to each patient's needs. Chris Bell, an acute care nurse practitioner who specializes ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

(TECX), a clinical-stage biotechnology company ... in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction. The interim analysis showed that TX45 resulted ...